Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Safety Considerations of Fluoroquinolones in the Elderly

An Update

Abstract

The fluoroquinolones ciprofloxacin, levofloxacin, moxifloxacin and gemifloxacin are widely used for the treatment of various types of bacterial infections. Overall, these antibacterial agents can be considered safe and well tolerated drugs. Comparative studies have evaluated the use of quinolones in elderly and younger populations. Although age per se does not seem to decrease their tolerability, specific adverse effects of the quinolones must be considered when they are chosen for antibacterial treatment.

Renal function declines consistently with age and doses of renally excreted quinolones (e.g. ofloxacin, levofloxacin, gatifloxacin) need to be adjusted if a clinically relevant reduction of creatinine clearance is identified. Reactions of the gastrointestinal tract, such as nausea, dyspepsia, vomiting or diarrhoea, are among the most often registered adverse drug reactions during therapy with fluoroquinolones. Treatment with a quinolone causes diarrhoea less frequently than treatment with other classes of antimicrobials. Conflicting data have been published with respect to the incidence of Clostridium difficile- associated diarrhoea in quinolone-treated patients. Hypersensitivity reactions, often manifested on the skin, occur less commonly during therapy with quinolones than, for example, during therapy with β-lactam antibacterials.

Adverse reactions of the CNS are of particular concern in the elderly population. Given the CNS excitatory effects of quinolones, elderly patients should be monitored carefully for such symptoms. It is likely that many signs of possible adverse reactions, such as confusion, weakness, loss of appetite, tremor or depression, are often mistakenly attributed to old age and remain unreported. Quinolones should be used with caution in patients with known or suspected CNS disorders that predispose to seizures (e.g. severe cerebral arteriosclerosis or epilepsy).

Quinolones can cause QT interval prolongation. They should be avoided in patients with known prolongation of the QT interval, patients with un-corrected hypokalaemia or hypomagnesaemia and patients receiving class IA (e.g. quinidine, procainamide) or class III (e.g. amiodarone, sotalol) anti-arrhythmic agents.

Tendinitis and tendon ruptures are recognized as quinolone-induced adverse effects that can occur during treatment or as late as several months after treatment. Chronic renal diseases, concomitant use of corticosteroids and age >60 years are known risk factors for quinolone-induced tendopathies.

Overall, the specific adverse-effect profile of quinolones must be considered when they are chosen for treatment of bacterial infections. Because of physiological changes in renal function and when certain co-morbidities are present, some special considerations are necessary when elderly patients are treated with these drugs.

This is a preview of subscription content, log in to check access.

Table I
Table II
Table III

References

  1. 1.

    Naber KG, Adam D. Classification of fluoroquinolones. Int J Antimicrob Agents 1998; 10: 255–7

  2. 2.

    Stahlmann R, Lode H. Fluoroquinolones in the elderly: safety considerations. Drugs Aging 2003; 20(4): 289–302

  3. 3.

    Carbonin P, Pahor M, Bernabei R, et al. Is age an independent risk factor of adverse drug reactions in hospitalized medical patients? J Am Geriatr Soc 1991; 39: 1093–9

  4. 4.

    Mamdani M, McNeely D, Evans G, et al. Impact of a fluoroquinolone restriction policy in an elderly population. Am J Med 2007; 120: 893–900

  5. 5.

    Iannini PB. The safety profile of moxifloxacin and other fluoroquinolones in special patient populations [published erratum appears in Curr Med Res Opin 2007; 23 (9): 303]. Curr Med Res Opin 2007; 23(6): 1403–13

  6. 6.

    Lode H, Allewelt M. Role of newer fluoroquinolones in lower respiratory tract infections [corrected and republished in J Antimicrob Chemother 2002; 50 (1): 151-4]. J Antimicrob Chemother 2002; 49(5): 709–12

  7. 7.

    Gomolin IH, Siami PF, Reuning-Scherer J, et al., and Oral Suspension Study Group. Efficacy and safety of ciprofloxacin oral suspension versus trimethoprim/sulfamethoxazole oral suspension for treatment of older women with acute urinary tract infection. J Am Geriatr Soc 2001; 49: 1606–13

  8. 8.

    Noreddin AM, Hoban DJ, Zhanel GG. Comparison of gatifloxacin and levofloxacin administered at various dosing regimens to hospitalised patients with community-acquired pneumonia: pharmacodynamic target attainment study using North American surveillance data for Streptococcus pneumoniae. Int J Antimicrob Agents 2005; 26(2): 120–5

  9. 9.

    Andriole VT, Haverstock DC, Choudhri SH. Retrospective analysis of the safety profile of oral moxifloxacin in elderly patients enrolled in clinical trials. Drug Saf 2005; 28(5): 443–52

  10. 10.

    Ball P, File TM, Twynholm M, et al. Efficacy and safety of gemifloxacin 320 mg once-daily for 7 days in the treatment of adult lower respiratory tract infections. Int J Antimicrob Agents 2001; 18(1): 19–27

  11. 11.

    Anzueto A, Niederman MS, Pearle J, et al. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy. Clin Infect Dis 2006; 42: 73–81

  12. 12.

    Shorr AF, Zadeikis N, Xiang JX, et al. A multicenter, randomized, double-blind, retrospective comparison of 5- and 10-day regimens of levofloxacin in a subgroup of patients aged > or=65 years with community-acquired pneumonia. Clin Ther 2005; 27(8): 1251–9

  13. 13.

    Nicholson SC, High KP, Gothelf S, et al. Gatifloxacin in community-based treatment of acute respiratory tract infections in the elderly. Diagn Microbiol Infect Dis 2002; 44(1): 109–16

  14. 14.

    Keam SJ, Croom KF, Keating GM. Gatifloxacin: a review of its use in the treatment of bacterial infections in the US. Drugs 2005; 65(5): 695–724

  15. 15.

    Graber H, Ludwig E, Arr M, et al. Difference in multiple-dose pharmacokinetics of ofloxacin in young and aged patients [abstract no. 94]. International Symposium on New Quinolones; 1986 Jul 17-19; Geneva

  16. 16.

    Chien SC, Chow AT, Natarajan J, et al. Absence of age and gender effects on the pharmacokinetics of a single 500-milligram dose of levofloxacin in healthy subjects. Antimicrob Agents Chemother 1997; 41: 1562–5

  17. 17.

    Perry CM, Ormrod D, Hurst M, et al. Gatifloxacin: a review of its use in the management of bacterial infections. Drugs 2002; 62(1): 169–207

  18. 18.

    Tequin™ (gatifloxacin) [US package insert]. Princeton NJ): Bristol-Myers Squibb Company, 2001

  19. 19.

    Balfour JA, Lamb HM. Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections. Drugs 2000; 59(1): 115–39

  20. 20.

    Wiseman LR, Balfour JA. Ciprofloxacin: a review of its pharmacological profile and therapeutic use in the elderly. Drugs Aging 1994; 4(2): 145–73

  21. 21.

    van Zanten AR, Polderman KH, van Geijlswijk IM, et al. Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study. J Crit Care 2008; 23(3): 422–30

  22. 22.

    Bhavnani SM, Andes DR. Gemifloxacin for the treatment of respiratory tract infections: in vitro susceptibility, pharmacokinetics and pharmacodynamics, clinical efficacy, and safety. Pharmacotherapy 2005; 25(5): 717–40

  23. 23.

    Lode HM, Schmidt-Ionas M, Stahlmann R. Gemifloxacin for community-acquired pneumonia. Expert Opin Investig Drugs 2008; 17(5): 779–86

  24. 24.

    Nicolle LE. Quinolones in the aged. Drugs 1999; 58Suppl. 2: 49–51

  25. 25.

    Breen J, Skuba K, Grasela D. Safety and tolerability of gatifloxacin, an advanced-generation, 8-methoxy fluoroquinolone. J Resp Dis 1999; 20 Suppl.: S70–6

  26. 26.

    Springsklee M, Reiter C, Meyer JM. Safety and tolerability of moxifloxacin (MXF) [abstract no. 260]. Antiinfect Drugs Chemother 2000; 17(1): 90

  27. 27.

    Ball P, Stahlmann R, Kubin R, et al. Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies. Clin Ther 2004; 26(7): 940–50

  28. 28.

    Levaquin®: prescribing information. Raritan NJ): Ortho-McNeil, 1999

  29. 29.

    Edlund C, Nord CE. Effect of quinolones on intestinal ecology. Drugs 1999; 58Suppl. 2: 65–70

  30. 30.

    Edlund C, Beyer G, Hiemer-Bau M, et al. Comparative effects of moxifloxacin and clarithromycin on the normal intestinal microflora. Scand J Infect Dis 2000; 32: 81–5

  31. 31.

    Ljungberg B, Nilsson-Ehle I, Edlund C, et al. Influence of ciprofloxacin on the colonic microflora in young and elderly volunteers: no impact of the altered drug absorption. Scand J Infect Dis 1990; 22: 205–8

  32. 32.

    Bartlett JG. Clinical practice: antibiotic-associated diarrhea. N Engl J Med 2002; 346(5): 334–9

  33. 33.

    Pépin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Inf Dis 2005; 41(9): 1254–60

  34. 34.

    Rao GG, Rao CSM, Starke I. Clostridium difficile-associated diarrhoea in patients with community-acquired lower respiratory infection being treated with levofloxacin compared with β-lactam-based therapy. J Antimicrob Chemother 2003; 51: 697–701

  35. 35.

    Mendez MN, Gibbs L, Jacobs RA, et al. Impact of a piperacillin-tazobactam shortage on antimicrobial prescribing and the rate of vancomycin-resistant enterococci and Clostridium difficile infections. Pharmacother 2006; 26(1): 61–7

  36. 36.

    Thomas C, Stevenson M, Riley TV. Antibiotics and hospital-acquired Clostridium difficile-associated diarrhoea: a systematic review. J Antimicrob Chemother 2003; 51(6): 1339–50

  37. 37.

    Blondeau JM. What have we learned about antimicrobial use and the risks for Clostridium difficile-associated diarrhoea? J Antimicrob Chemother 2009; 63(2): 238–42

  38. 38.

    Mehlhorn AJ, Brown DA. Safety concerns with fluoroquinolones. Ann Pharmacother 2007; 41(11): 1859–66

  39. 39.

    Stahlmann R. Clinical toxicological aspects of fluoroquinolones. Toxicol Lett 2002; 127: 269–77

  40. 40.

    Kawahara K, Kawahara M, Goto T, et al. Penetration of sparfloxacin into the human spinal fluid: a comparative study with 5 other fluoroquinolones. Chemotherapy 1991; 39: 149–57

  41. 41.

    Davey PG, Charter M, Kelly S, et al. Ciprofloxacin and sparfloxacin penetration into human brain tissue and their activity as antagonists of GABAA receptor of rat vagus nerve. Antimicrob Agents Chemother 1994; 38: 1356–62

  42. 42.

    Leone M, Sampol-Manos E, Santelli D, et al. Brain tissue penetration of ciprofloxacin following a single intravenous dose. J Antimicrob Chemother 2002; 50(4): 607–9

  43. 43.

    Kushner JM, Peckman HJ, Snyder CR. Seizures associated with fluoroquinolones. Ann Pharmacother 2001; 35: 1194–8

  44. 44.

    Takayama S, Hirohashi M, Kato M, et al. Toxicity of quinolone antimicrobial agents. J Toxicol Environment Health 1995; 45: 1–45

  45. 45.

    Owens RC, Ambrose PG. Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis 2005; 41: S144–57

  46. 46.

    Schmuck G, Schürmann A, Schlüter G. Determination of the excitatory potencies of fluoroquinolones in the central nervous system by an in vitro model. Antimicrob Agents Chemother 1998; 42: 1831–6

  47. 47.

    Shakeri-Nejad K, Stahlmann R. Drug interactions during therapy with three major groups of antimicrobial agents. Expert Opin Pharmacother 2006; 7(6): 639–51

  48. 48.

    Brouwers EE, Söhne M, Kuipers S, et al. Ciprofloxacin strongly inhibits clozapine metabolism: two case reports. Clin Drug Investig 2009; 29: 59–63

  49. 49.

    Lipsky BA, Baker CA. Fluoroquinolone toxicity profiles: a review focusing on newer agents. Clin Infect Dis 1999; 28: 352–64

  50. 50.

    Van Bambeke F, Tulkens PM. Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes. Drug Saf 2009; 32(5): 359–78

  51. 51.

    Ball P, Mandell L, Patou G, et al. A new respiratory fluoroquinolone, oral gemifloxacin: a safety profile in context. Int J Antimicrob Agents 2004; 23: 421–9

  52. 52.

    Rubinstein E, Camm J. Cardiotoxicity of fluoroquinolones. J Antimicrob Chemother 2002; 49: 593–6

  53. 53.

    Anderson ME, Mazur A, Yang T, et al. Potassium current antagonist properties and proarrhythmic consequences of quinolone antibiotics. J Pharmacol Exp Ther 2001; 296(3): 806–10

  54. 54.

    Kang J, Wang L, Chen XL, et al. Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. Mol Pharmacol 2001; 59: 122–6

  55. 55.

    Church D, Haverstock D, Andriole VT. Moxifloxacin: a review of its safety profile based on worldwide clinical trials. Todays Therapeutic Trends 2000; 18: 205–23

  56. 56.

    Bertino JS, Owens RC, Carnes TD, et al. Gatifloxacin-associated corrected QT-interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors. Clin Infect Dis 2002; 34: 861–3

  57. 57.

    Owens RC, Ambrose PG. Torsades de pointes associated with fluoroquinolones. Pharmacotherapy 2002; 22: 663–8

  58. 58.

    Amankwa K, Krishnan SC, Tisdale JE. Torsades de pointes associated with fluoroquinolones: importance of concomitant risk factors. Clin Pharmacol Ther 2004; 75(3): 242–7

  59. 59.

    Morganroth J, DiMarco JP, Anzueto A, et al. A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia. Chest 2005; 128: 3398–406

  60. 60.

    Avelox™ (moxifloxacin hydrochloride) tablets [US package insert]. Wayne NJ): Bayer HealthCare Pharmaceuticals Inc., 1999

  61. 61.

    Sherman O, Beizer JL. Possible ciprofloxacin-induced acute cholestatic jaundice. Ann Pharmacother 1994; 28(10): 1162–4

  62. 62.

    Ho CC, Chen YC, Hu FC, et al. Safety of fluoroquinolone use in patients with hepatotoxicity induced by anti-tuberculosis regimens. Clin Infect Dis 2009; 48(11): 1526–33

  63. 63.

    Lode HM, Schmidt-Ionas M. Moxifloxacin: update and perspectives after 8 years of usage. Exp Rev Resp Med 2008; 2: 443–53

  64. 64.

    Shlaes DM, Moellering RC. Telithromycin and the FDA: implications for the future. Lancet Infect Dis 2008; 8(2): 83–5

  65. 65.

    Grayson ML. Synthetic antibacterial and antiparasitic drugs. In: Kucers A, Crowe SM, Grayson ML, et al., editors. The use of antibiotics: a clinical review of antibacterial, antifungal and antiviral drugs. 5th ed. Oxford: Butterworth, Heinemann, 1997: 981–1060

  66. 66.

    Lomaestro BM. Fluoroquinolone-induced renal failure. Drug Saf 2000; 22: 479–85

  67. 67.

    Famularo G, De Simone C. Nephrotoxicity and purpura associated with levofloxacin. Ann Pharmacother 2002; 36(9): 1380–2

  68. 68.

    Ramalakshmi S, Bastacky S, Johnson JP. Levofloxacin-induced granulomatous interstitial nephritis [abstract]. Am J Kidney Dis 2003; 41(2): E7

  69. 69.

    Stratta P, Lazzarich E, Canavese C, et al. Ciprofloxacin crystal nephropathy. Am J Kidney Dis 2007; 50(2): 330–5

  70. 70.

    Chopra N, Fine PL, Price B, et al. Bilateral hydronephrosis from ciprofloxacin induced crystalluria and stone formation. J Urology 2000; 164: 438

  71. 71.

    Sendzik J, Lode H, Stahlmann R. Quinolone-induced arthropathy: an update focusing on new mechanistic and clinical data. Int J Antimicrob Agents 2009; 33(3): 194–200

  72. 72.

    Förster C, Kociok K, Shakibaei M, et al. Quinolone-induced cartilage lesions are not reversible in rats. Arch Toxicol 1996; 70: 474–81

  73. 73.

    Förster C, Schwabe R, Lozo E, et al. Quinolone-induced arthropathy: exposure of magnesium-deficient aged rats or immature rats, mineral concentrations in target tissues and pharmacokinetics. Arch Toxicol 1997; 72: 26–32

  74. 74.

    Stahlmann R, Förster C, Shakibaei M, et al. Magnesium deficiency induces joint cartilage lesions in juvenile rats which are identical with quinolone-induced arthropathy. Antimicrob Agents Chemother 1995; 39: 2013–8

  75. 75.

    Lozo E, Riecke K, Schwabe R, et al. Synergistic effect of ofloxacin and magnesium deficiency on joint cartilage in immature rats. Antimicrob Agents Chemother 2002; 46: 1755–9

  76. 76.

    Pfister K, Mazur D, Vormann J, et al. Diminished ciprofloxacin-induced chondrotoxicity by supplementation with magnesium and vitamin E in immature rats. Antimicrob Agents Chemother 2007; 51(3): 1022–7

  77. 77.

    Van der Linden PD, van Puijenbroek EP, Feenstra J, et al. Tendon disorders attributed to fluoroquinolones: a study on 42 spontaneous reports in the period 1988 to 1998. Arthritis Rheum 2001; 45: 235–9

  78. 78.

    Damuth E, Heidelbaugh J, Malani PN, et al. An elderly patient with fluoroquinolone-associated Achilles tendinitis. Am J Geriatr Pharmacother 2008; 6(5): 264–8

  79. 79.

    Parmar C, Meda KP. Achilles tendon rupture associated with combination therapy of levofloxacin and steroid in four patients and a review of the literature. Foot Ankle Int 2007; 28: 1287–9

  80. 80.

    Vyas H, Krishnaswamy G. Images in clinical medicine. Quinolone-associated rupture of the Achilles’ tendon [letter]. N Engl J Med 2007; 357(20): 2067

  81. 81.

    Kahn MF, Hayem G. Tendons and fluoroquinolones: unresolved issues. Rev Rhum Engl Ed 1997; 64: 437–9

  82. 82.

    Pierfitte C, Royer RJ. Tendon disorders with fluoroquinolones. Therapie 1996; 51: 419–20

  83. 83.

    Van der Linden PD, van de Lei J, Nab HW, et al. Achilles tendinitis associated with fluoroquinolones. Br J Clin Pharmacol 1999; 48: 433–7

  84. 84.

    Simonin M-A, Gegout-Pottie P, Minn A, et al. Pefloxacin-induced Achilles tendon toxicity in rodents: biochemical changes in proteoglycan synthesis and oxidative damage to collagen. Antimicrob Agents Chemother 2000; 44: 867–72

  85. 85.

    Shakibaei M, Pfister K, Schwabe R, et al. Ultrastructure of Achilles tendons of rats treated with ofloxacin and fed a normal or magnesium-deficient diet. Antimicrob Agents Chemother 2000; 44: 261–6

  86. 86.

    Shakibaei M, Stahlmann R. Ultrastructure of Achilles tendon from rats after treatment with fleroxacin. Arch Toxicol 2001; 75: 97–102

  87. 87.

    Shakibaei M, Baumann-Wilschke I, Stahlmann R. Quinolone-induced changes in Achilles tendons from rats persist for several months [poster no. P130]. J Antimicrob Chemother 2001;47Suppl. S1: 49

  88. 88.

    Saraya A, Yokokura M, Gonoi T, et al. Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K+ channels. Eur J Pharmacol 2004; 497(1): 111–7

  89. 89.

    Ambrose PG, Bhavnani SM, Owens Jr RC. Clinical pharmacodynamics of quinolones. Infect Dis Clin North Am 2003; 17(3): 529–43

  90. 90.

    Ambrose PG, Bhavnani SM, Cirincione BB, et al. Gatifloxacin and the elderly: pharmacokinetic-pharmacodynamic rationale for a potential age-related dose reduction. J Antimicrob Chemother 2003; 52(3): 435–40

  91. 91.

    Park-Wyllie LY, Juurlink DN, Kopp A, et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med 2006; 354(13): 1352–61

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this review. Ralf Stahlmann has no conflicts of interest that are directly relevant to the content of this review. Hartmut Lode has acted as a consultant to and/or received honoraria from Bayer-Schering, Sanofi-Aventis, Pfizer and Wyeth.

Author information

Correspondence to Professor Ralf Stahlmann.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Stahlmann, R., Lode, H. Safety Considerations of Fluoroquinolones in the Elderly. Drugs Aging 27, 193–209 (2010). https://doi.org/10.2165/11531490-000000000-00000

Download citation

Keywords

  • Fluoroquinolones
  • Ofloxacin
  • Quinolones
  • Levofloxacin
  • Moxifloxacin